JP Morgan Chase’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

JP Morgan Chase’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-53,522	Closed	-$14K	–	7549
2023 Q1	$14K	Buy	53,522 +14,507	+37%	+$13.1K	﹤0.01%	6061
2022 Q4	$46K	Buy	39,015 +1,865	+5%	+$3.92K	﹤0.01%	5655
2022 Q3	$76K	Sell	37,150 -54,819	-60%	-$93K	﹤0.01%	5410
2022 Q2	$142K	Buy	91,969 +90,569	+6,469%	+$354K	﹤0.01%	5242
2022 Q1	$7K	Buy	+1,400	New	+$6.36K	﹤0.01%	6280
2021 Q4	–	Sell	-92,831	Closed	-$923K	–	7129
2021 Q3	$923K	Buy	+92,831	New	+$918K	﹤0.01%	4373

JP Morgan Chase's PEAR Position: Q2 2023 in Review

JP Morgan Chase sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 53,522 shares — an estimated $14K sold.

JP Morgan Chase first reported a position in PEAR in Q3 2021 and held it in 6 quarters. The position peaked at $923K in Q3 2021. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

JP Morgan Chase reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
JP Morgan Chase sold 53,522 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $14K.
JP Morgan Chase first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2021 and held it in 6 quarters.
JP Morgan Chase's Pear Therapeutics, Inc. Class A Common Stock position peaked at $923K in Q3 2021.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.